Pituitary adenomas (PA) account for approximately 15% of all intracranial neoplasms.
Pituitary adenomas can be of different subtypes based on the cell of origin or associated …

Background Pituitary carcinomas (PC) are uncommon neuroendocrine tumors, accounting
for 0.1% of all pituitary tumors. The diagnosis of PC is based on the presence of metastases …

Pituitary tumors are common in the general population. Since neuroimaging techniques
have improved, pituitary tumors are more often diagnosed incidentally. About 16.7% of the …

Especially given the rarity of aggressive pituitary tumors and carcinomas, and the scarcity of
available data, the ESE guidelines are of tremendous help, providing clinicians with vital …

Recent case reports have documented the efficacy of temozolomide therapy in some
aggressive pituitary adenomas and pituitary carcinomas resistant to multimodality therapy …

Purpose Knowledge of biological behavior is crucial for clinical management of functioning
pituitary macroadenomas. For recurrent cases unresponsive to standard treatment …

The optimal treatment of pituitary carcinomas (PC) is unknown. Treatment includes surgical
resection, radiation, and more recently, temozolomide (TMZ). Pituitary adenomas have …

While recent progress has been made in identifying biomarkers of aggressive behavior and
new treatment options, many questions remain. Treatment decisions require …

BACKGROUND: Currently, no effective alternative treatment exists for progressive,
regrowing, nonfunctioning pituitary adenomas (NFPA) that are resistant to conventional …

Purpose Refractory prolactinomas resistant to dopamine agonists (DAs) pose a clinical
challenge. Temozolomide (TMZ) is a recommended treatment option, but its effects are …